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Abstract
Each year, hundreds of millions of new cases of curable sexually transmitted infections (STIs) occur worldwide resulting in
reproductive and other serious sequelae, as well as enhanced transmission of HIV. The clinical management
and control of these STIs should include as a minimum access to services that provide timely and accurate
diagnostic testing together with effective treatment. The provision of appropriate treatment is challenged by
the development of increasing antimicrobial resistance, in particular with gonorrhoea and Mycoplasma genitalium
infections, requiring new treatments and management algorithms. In addition, infections such as chlamydia, syphilis
and trichomoniasis, which show few signs of resistance, are nevertheless highly prevalent and require better public
health control measures. While these may be achievable in high income countries, they are still beyond the reach of
many low and middle income countries, making substantial improvements in STI management and reductions in STI
prevalence challenging.
Editorial
In 2008, the World Health Organization (WHO) estimated
that globally there were 499 million new cases of curable
sexually transmitted infections (STIs), including gonor-
rhoea, chlamydia, syphilis, and trichomoniasis, occurring
every year. Discouragingly, this was even higher than the
estimated 448 million cases reported in 2005 [1]. Each of
these cases, mostly detected in young men and women,
represents a person diagnosed with what is generally a
stigmatizing condition with potentially serious reproduct-
ive or other sequelae. These include ectopic pregnancy,
pelvic inflammatory disease, preterm birth, female infertil-
ity, neonatal death, and enhanced acquisition and trans-
mission of HIV, just to name a few [1, 2]. This begs the
question, what more can be done to improve the diagnosis,
treatment and control these curable infections? This spe-
cial issue of BMC Infectious Diseases focuses on the chal-
lenges confronting the clinical management of several key
treatable STI and STI related syndromes with experts in
the field offering opinions on where future efforts should
be focused. These include infections where antimicrobial
resistance is established and increasing as well as infections
that show few signs of resistance but are nevertheless
highly prevalent with the need for better control.
Over several decades, Neisseria gonorrhoeae has succes-
sively developed antimicrobial resistance to multiple clas-
ses of antibiotics and has been identified by the United
States Center for Disease Control as one of the top urgent
antibiotic resistance threats [3]. Case reports of high level
resistance to ceftriaxone have rung alarm bells and further
stimulated efforts towards the discovery of new alternative
treatments [4, 5]. In this issue Unemo reviews these and
other cases, highlights the need for continued vigilance,
and discusses potential new agents in the development
pipeline aimed at combatting this mercurial bacterium [6].
Mycoplasma genitalium is a common cause of male ur-
ethritis and is found in women with pelvic inflammatory
disease [7]. Like gonorrhoea, Mycoplasma genitalium
has developed increasing resistance to various antibiotic
classes, a problem that is currently under recognized
and in pressing need for greater attention. Jensen et al.
provide a detailed overview of data pointing to the grow-
ing antimicrobial resistance evident with M. genitalium
infections [8]. It is difficult to envisage any reversal in
these trends without the introduction of fundamental
measures such as widespread routine diagnostic testing
for M. genitalium, availability of testing for antimicrobial
resistance, and ongoing surveillance. In many high income
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countries these are in place for gonorrhoea but notably
absent for M. genitalium.
Moi et al. explore the treatment implications of M.
genitalium resistance further in their proposed guidance
on the clinical management of men presenting with
non-gonococcal urethritis, one of the most common STI
related syndromes [9]. This currently presents a major
clinical challenge as most urethral chlamydia will clear
with azithromycin or doxycycline but both of these anti-
biotics are becoming increasingly ineffective at eliminat-
ing M. genitalium urethritis. Moi et al. float the idea of
withholding treatment from men presenting with non-
gonococcal urethritis until a diagnosis of chlamydia or
M. genitalium is confirmed by laboratory testing. This
concept is worthy of further exploration and may need
to be tailored to different clinical settings. Better drugs
and more rational management algorithms for non-
gonococcal urethritis are needed.
While antimicrobial resistance to chlamydia is fortu-
nately not currently contributing to the treatment failures
to any significant extent, there continues to be uncertainty
over whether single dose azithromycin, which has been
the mainstay of treatment for uncomplicated genital chla-
mydial infections for many years, or doxycycline, should
be the preferred treatment for chlamydia [10]. The ques-
tion of whether doxycycline should replace single dose
azithromycin as first line therapy for non-gonococcal ur-
ethritis in men based on efficacy against chlamydia and
possible induction of macrolide resistant M. genitalium
warrants further investigation [10]. A growing number of
observational studies have suggested that azithromycin is
inferior to doxycycline for the treatment of rectal chla-
mydia [11]. Kong et al. delve into these issues in their re-
view of chlamydia treatment and call for randomized
controlled trials to definitively determine if doxycycline
should replace single dose azithromycin for the treatment
of rectal chlamydia [12]. Several studies have pointed to
rectal chlamydia being prevalent among not only men
who have sex with men, but also women [13].
Globally, syphilis remains a pressing concern with inter-
national data indicating a resurgence of syphilis among
men who have sex with men and unacceptably high rates
of congenital syphilis [14, 15]. To highlight the magnitude
of this, the WHO estimated that in 2008 syphilis infec-
tions in pregnancy led to 305,000 fetal and neonatal
deaths and 215,000 infants at risk of dying from prematur-
ity, low birth weight or congenital syphilis worldwide [1].
Syphilis also drives acquisition of HIV infections, worrying
as both syphilis and HIV are overrepresented in many
populations of MSM [16]. In their review on the chal-
lenges in the management of adult syphilis, Tuddenham
et al. revisit whether standard treatments for syphilis are
adequate in HIV positive patients [17]. They also discuss
uncertainty over the management of patients who remain
serofast following syphilis treatment and developments in
laboratory diagnostics.
Given the extraordinarily high global prevalence of
Trichomonas vaginalis and its potential to promote HIV
transmission, further investment into the optimal diag-
nosis, treatment, and control of T. vaginalis is clearly
needed. Kissinger provides a comprehensive review on
the epidemiology, diagnosis and management of this in-
fection [18]. The fact that T. vaginalis screening of
HIV positive women in the US alone would save an esti-
mated $160 million in lifetime costs from new HIV infec-
tions prevented underscores the public health importance
of the optimal detection and management of this proto-
zoal infection [19].
While not usually regarded as a curable STI, bacterial
vaginosis is common among women presenting with va-
ginal discharge and linked to reproductive sequelae and
enhanced HIV transmission [20, 21]. Bradshaw et al. discuss
emerging areas for research into bacterial vaginosis
aimed at reducing recurrence of this condition which is
common following treatment [22]. These include studies to
help elucidate the postulated role of reinfection from
sexual partners, vaginal microbiota, and vaginal biofilm
in the pathogenesis of bacterial vaginosis and possible
interventions targeting these.
The WHO global strategy for the prevention and con-
trol of STI stipulates that comprehensive STI manage-
ment should include as a minimum, accurate diagnosis
by syndrome or laboratory diagnosis, plus effective treat-
ment to prevent complications and further transmission
[23]. While laboratory testing is taken for granted in high
income countries, they are still beyond the reach of many
low and middle income countries. Better performing point
of care tests and use of self-collected sampling for several
STI bring some hope of more access to diagnostic testing.
Similarly, while reasonable adherence by health providers
to local treatment guidelines governing antibiotic use for
STI should be expected in well-resourced countries, less
regulated use of antibiotics in resource limited settings
threatens to only compound antimicrobial resistance. Stark
differences in levels of health funding, health service infra-
structure, together with what is often a low priority for STI
on the political agenda, means meaningful improvements
in STI management with reductions in STI prevalence will
for the foreseeable future remain challenging.
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